Results 111 to 120 of about 26,042 (243)

ETV6::ABL1-Positive Myeloid Neoplasm: A Case of a Durable Response to Imatinib Mesylate without Additional or Previous Treatment. [PDF]

Int J Mol Sci, 2023
Bochicchio MT, Marconi G, Baldazzi C, Bandini L, Ruggieri F, Lucchesi A, Agostinelli C, Sabattini E, Orsatti A, Ferrari A, Capirossi G, Servili C, Ghelli Luserna di Rorà A, Martinelli G, Simonetti G, Rosti G.   +15 more
europepmc   +1 more source

Gastrointestinal Langerhans cell histiocytosis responding to cladribine and imatinib mesylate [PDF]

, 2010
Gastrointestinal involvement in Langerhans cells histiocytosis (LCH) is extremely rare. An optimal treatment regimen is not defined yet and its prognosis is relatively poor.
Agreda Vásquez, Gladys Patricia, Lome Maldonado, Carmen, Oviedo, Edgar, Popoca Barriga, Ulises, Sánchez Guerrero, Sergio Arturo   +4 more
core  

Imatinib mesylate affects tyrosine kinase activity in both leukemic and normal primary mononuclear blood cells [PDF]

, 2006
Kateřina Kuželová, Dana Grebeňová, Michaela Pluskalová, Iuri Marinov, Hana Klamová, Zbyněk Hrkal   +5 more
openalex   +1 more source

Falla cardiaca asociada con el uso de imatinib mesilato: Reporte de un caso Heart failure associated to imatinib mesylate use: Case report

Revista Colombiana de Cardiología, 2008
La cardiotoxicidad por medicamentos es un evento cada vez más frecuente en la práctica clínica diaria. Inhibidores de la proteína de fusión Brc/Abl como el imatinib mesilato, son una nueva herramienta para el tratamiento de algunas neoplasias ...
Clara Saldarriaga, Jairo A Rendón, Juan M Senior   +2 more
doaj  

Computational and mechanistic studies on the effect of galactoxyloglucan: Imatinib nanoconjugate in imatinib resistant K562 cells

Tumor Biology, 2017
Imatinib mesylate, a BCR/ABL fusion protein inhibitor, is the first-line treatment against chronic myelogenous leukemia. In spite of its advantageous viewpoints, imatinib still has genuine impediments like undesirable side effects and tumor resistance ...
Alphy Rose James, BS Unnikrishnan, R Priya, Manu M Joseph, TK Manojkumar, K Raveendran Pillai, R Shiji, GU Preethi, P Kusumakumary, TT Sreelekha   +9 more
doaj   +1 more source

Supplemental Figure 1 from Combination of Imatinib Mesylate and AKT Inhibitor Provides Synergistic Effects in Preclinical Study of Gastrointestinal Stromal Tumor

, 2023
Phillip Zook, Harsh B. Pathak, Martin G. Belinsky, Lawrence Gersz, Karthik Devarajan, Yan Zhou, Andrew K. Godwin, Margaret von Mehren, Lori Rink   +8 more
openalex   +1 more source

Antiproliferation effect of imatinib mesylate on MCF7, T-47D tumorigenic and MCF 10A nontumorigenic breast cell lines via PDGFR-β, PDGF-BB, c-Kit and SCF genes

Drug Design, Development and Therapy, 2017
Ali Kadivar,1 Behnam Kamalidehghan,1 Hamid Akbari Javar,2 Benyamin Karimi,3 Reihaneh Sedghi,4 Mohamed Ibrahim Noordin1 1Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2Department of Pharmaceutics, Faculty of ...
Kadivar A, Kamalidehghan B, Akbari Javar H, Karimi B, Sedghi R, MI Noordin   +5 more
doaj  

Adherence and/or discontinuation of imatinib mesylate in patients with chronic myeloid leukemia

Brazilian Journal of Pharmaceutical Sciences
Adherence to imatinib mesylate improves clinical outcomes and promotes a reduction in health expenditure. However, treatment duration and lack of efficacy decrease adherence to pharmacotherapy, resulting in increased mortality associated with Chronic ...
Alexandra Rodrigues Alves, William Gustavo Lima, Michelly Martins Nagai, João Paulo Vilela Rodrigues, Lorena Rocha Ayres   +4 more
doaj   +1 more source

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate. [PDF]

Cureus, 2023
Batra J, Ankireddypalli AR, Kanugula AK, Gorle S, Kaur J.   +4 more
europepmc   +1 more source

Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal Tumors [PDF]

, 2002
George D. Demetri, Margaret von Mehren, Charles D. Blanke, Annick D. Van den Abbeele, Burton Eisenberg, Peter Roberts‎, Michael C. Heinrich, David A. Tuveson, Samuel Singer, Milos J. Janicek, Jonathan A. Fletcher, Stuart G. Silverman, Sandra Silberman, Renaud Capdeville, Beate Kiese, Bin Peng, Saša Dimitrijević, Brian Druker, Christopher L. Corless, Christopher D.�M. Fletcher, Heikki Joensuu   +20 more
openalex   +1 more source